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A B S T R A C TBackground: Pneumococcal universal vaccination in Hong Kong was
introduced in 2009. Objectives: We assessed the health and economic
impact of the 10-valent pneumococcal nontypeable Haemophilus
influenzae protein D conjugate vaccine (PCV-10) compared with the
current 13-valent pneumococcal conjugate vaccine (PCV-13) recom-
mended for Hong Kong in 2011, providing new elements to be
considered by public health authorities in the future decision-
making process for pneumococcal vaccines in this country. Methods:
An analytical model was used to estimate the annual economic and
health outcomes of invasive pneumococcal disease (IPD), community-
acquired pneumonia, and acute otitis media (AOM), including non-
typeable H. influenzae–related AOM, for a birth cohort in Hong Kong
from the payer perspective with a 10-year horizon. Clinical impact
including morbidity-mortality, quality-adjusted life-years (QALYs),
incremental costs, and cost-effectiveness comparing PCV-10 and
PCV-13 were estimated. Probabilistic sensitivity analyses by using
alternate scenarios were performed. Results: Model projections indi-
cate that PCV-13 and PCV-10 have approximately equivalent impactsee front matter Copyright & 2013, International
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ondence to: Jeffrey Cheah School of Medicine andon the prevention of deaths caused by IPD and pneumonia. PCV-13 is
projected to prevent 6 additional cases of IPD, whereas PCV-10 is
projected to prevent 13,229 additional AOM cases and 101 additional
QALYs. For the base case, PCV-10 vaccination is estimated to save 44.6
million Hong Kong dollars (34.1 million Hong Kong dollars dis-
counted). Sensitivity analysis indicated that PCV-10 would generate
more QALYs and save costs as compared with PCV-13. Conclusions:
Universal infant vaccination with new available pneumococcal vac-
cines is expected to generate a significant additional impact on
reducing the burden of pneumococcal diseases in Hong Kong. PCV-
10 vaccination would be potentially a cost-saving strategy compared
with PCV-13 vaccination, generating better cost offsets and higher
QALY gains.
Keywords: cost-effectiveness, Hong Kong, PCV-10, PCV-13,
pneumococcal conjugate vaccine, pneumococcal disease.
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Pneumococcal pneumonia and invasive pneumococcal disease
(IPD) are important causes of morbidity and mortality worldwide
[1]. In developed countries, young children and the elderly are at
particularly high risk [2].
Streptococcus pneumoniae (S. pneumoniae) diseases and acute
otitis media (AOM) have led to a significant public health
problem, especially in the Asia-Pacific region, including Hong
Kong, Singapore, Korea, and Taiwan [3]. Before pneumococcal
conjugate vaccines (PCVs) were available in Hong Kong, the
burden of IPD mainly affected children younger than 5 years(15.6 cases per 100,000) and adults 65 years and older (10.2 cases
per 100,000) [4].
The 7-valent PCV (PCV-7) was licensed in October 2005 and
was available only on private market. After the early introduc-
tion of PCV-7 (2005–2009) in the region for children younger than
5 years when only limited vaccine coverage was achieved, the
proportion of PCV-7 serotypes in laboratory surveillance from
different hospitals decreased significantly in children younger
than 5 years and adults 65 years and older. Nonetheless, sero-
types 6A and 19A increased slightly in children, especially for the
multidrug-resistant serotype 19A ST320 clone [5]. In addition,
similar findings were found in carriage in which PCV-7 serotypesSociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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with a slight increase in the non–PCV-7 serotypes [6].
PCV-7 was included in the childhood immunization program
for Hong Kong in September 2009 and recommended for children
younger than 2 years under a catch-up in Hong Kong. This
decision was supported by an economic evaluation that con-
cluded that PCV-7 would be a cost-effective intervention [7].
Passive laboratory surveillance for IPD in all age groups is not
routinely performed in most public hospitals in Hong Kong
owing to resource constraints by local authorities to assess
serotype distribution and antimicrobial resistance of IPD isolates,
including potential vaccination impact and secular trends, to
support periodic discussions on pneumococcal vaccine selection
to continue universal vaccination in this region. Nevertheless,
government’s central data revealed that in 2010, the most
common invasive pneumococcal serotypes were serotypes 3
and 14 for all ages, and for children younger than 5 years,
serotype 3 isolates constituted 40.0% of invasive pneumococcal
isolates [8].
Subsequently, two new vaccines were licensed in the coun-
try: the 10-valent pneumococcal nontypeable Haemophilus
influenzae (H. influenzae) protein D conjugate vaccine (PCV-10,Fig. 1 – (A) Model structure. (B) Modeled age compartments and
pneumococcal nontypeable Haemophilus influenzae protein D con
vaccine.Synflorix, GlaxoSmithKline Vaccines, London, United Kingdom)
and the 13-valent PCV (PCV-13, Prevenar 13, Wyeth, Madison, NJ,
USA). In October 2010, PCV-10 replaced PCV-7 in the govern-
ment’s childhood immunization program, extending the catch-
up to March 2011 for children born between September 2007 and
June 2009. Later, in December 2011, PCV-13 was recommended
for universal vaccination [9].
The licensure of PCV-10 and PCV-13 was approved on the
basis of noninferiority comparisons with PCV-7 on a serotype-by-
serotype basis by using enzyme-linked immunosorbent assay
and opsonophagocytic assay criteria [10,11]. These vaccines
differ in serotype coverage and carrier protein. PCV-10 was
developed by using protein D (derived from a highly conserved
nontypeable H. influenzae [NTHi] cell surface lipoprotein) as a
carrier, and studies with precursor vaccine have indicated that
it might offer additional protection against AOM caused by
NTHi [12].
Because there is limited evidence of economic evaluations
comparing PCV-10 and PCV-13 in Asian countries [13], we con-
ducted this updated cost-effectiveness analyses with the aim to
examine the health and economic impact of PCV-10 versus PCV-13
in the public sector of Hong Kong.vaccine efficacy periods. AOM, acute otitis media; PCV-10,
jugate vaccine; PCV-13, 13-valent pneumococcal conjugate
Table 1 – Parameter values used in the economic model.
Source
1. Demographics
Population by age group
Age group (y) n %
0–4 249,235 3.5
[15]
5–9 243,209 3.4
10–14 331,116 4.7
15–24 875,234 12.4
25–44 2,219,405 31.4
45–64 2,212,065 31.3
Z65 941,312 13.3
Total 7,071,576 100
2. Epidemiology
Pneumococcal meningitis
Age group (y) Incidence per
100,000
Case-fatality
ratio (%)
[16]
o1 1.9 9.0
1 1.9 9.0
2–4 1.0 9.0
5–9 0.2 9.0
10–64 0.1 13.2
Z65 0.2 30.4
Pneumococcal bacteremia
[16]
Age group (y) Incidence per
100,000
Case-fatality
ratio (%)
o1 4.2 4.6
1 4.2 4.6
2–4 2.8 4.6
5–9 1.2 4.6
10–64 0.2 17.5
65–89 4.1 34.8
Z90 4.1 40.0
All-cause pneumonia
Age group (y) Hospitalization
rate per
100,000
Case-fatality
ratio (%)
o2 1,047.5 0.2
[16]3–5 847.7 0.2
6–10 640.0 0.2
Acute otitis media
Age group (y) GP consultation
rate per 100,000
Total no. of
myringotomy
procedures per
100,000
o1 15,165.8 1,765.0
[17]
1 29,030.7 1,717.3
2–4 27,276.9 1,829.8
5–9 14,791.2 16,720.9
10–64 1,532.0 1,201.8
Z65 6,531.4 0.0
Mortality rates: general population
Age group (y) Rate per 100,000
o10 34.7
[15]
10–19 12.1
20–29 33.2
30–39 61.7
40–49 133.2
50–59 345.3
60–69 920.1
70–79 2,603.5
80–89 8,493.0
Z90 8,493.0
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Table 1 – continued
Source
Serotype distribution
Age group (y) PCV-10
serotypes (%)
Serotype 3 (%) Serotype 6A
(%)
Serotype 19A
(%)
PCV-13
serotypes (%)
o5 68.6 2.9 7.1 12.9 91.4
[5]
5–17 66.7 0.0 6.6 0.0 73.3
18–64 53.3 19.8 2.7 2.2 78.0
Z65 47.0 20.6 2.0 2.0 71.6
3. Direct costs
Episode HKD
Meningitis—first year (acute episode) 103,408
[7]
Bacteremia—hospitalized 68,641
Bacteremia—outpatient 700
Pneumonia—hospitalized 42,149
Pneumonia—outpatient 700
AOM-hospitalized myringotomy 4,206
AOM GP consultations 215
4. Disutilities
Episode QALYs lost
Meningitis—inpatient 0.023
[17,22]
Bacteremia—inpatient 0.008
Pneumonia—inpatient 0.008
Pneumonia—outpatient 0.006
AOM—outpatient 0.005
AOM-hospitalized myringotomy 0.005
5. Vaccine effectiveness assumptions
Episode PCV-10 (%) PCV-13 (%)
IPD (vs. vaccine types) 94.7 94.7 [23]
All-cause pneumonia 23.4 23.4 [24–29]
AOM total vaccine efficacy 22.9 11.3
[12,22,30]
AOM (vs. vaccine types) 57.6 57.6
AOM (vs. nonvaccine types)y 33.0 33.0
AOM (vs. NTHi)y 35.6 11.0
Myringotomies (Streptococcus pneumoniae
and NTHi)
65.8 32.6
AOM, acute otitis media; GP, general practitioner; HKD, Hong Kong dollars; IPD, invasive pneumococcal disease; NTHi, nontypeable
Haemophilus influenzae; NVT, nonvaccine serotype; PCV-10, pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine;
PCV-13, 13-valent pneumococcal conjugate vaccine; QALYs, quality-adjusted life-years; VT, vaccine serotype.
 VE AOM ¼ VEVT  % S. pneumoniae vaccine serotypes þ VENVT  % S. pneumoniae nonvaccine serotypes þ VENTHi  % NTHi AOM cases.
Here AOM total VE ¼ AOM total vaccine efficacy; VEVT ¼ vaccine efficacy against vaccine serotypes – % S. pneumoniae VT 25.7% PCV-10 vs. 29.5%
PCV-13; VENVT ¼ vaccine efficacy against nonvaccine serotypes  % S. pneumoniae NVT 10.2% PCV-10 vs. 6.4% PCV-13; VENTHi ¼ vaccine efficacy
against disease caused by Haemophilus influenzae including NTHi  32.3% PCV-10 vs. 32.3% PCV-13.
y Negative values ¼ serotype replacement.
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Model Structure
A Markov cohort model with a 10-year horizon was developed to
project the impact of vaccination on the incidence of pneumo-
coccal (invasive and noninvasive) and NTHi (noninvasive) infec-
tions in a Hong Kong birth cohort of children from a payer
perspective.
Our analysis used a model developed previously in Microsoft
Excel adapted with demographic, epidemiological, and disease
management data specific for Hong Kong [14]. It comprised a
decision-making Markov model that terminates in 10 mutually
exclusive health outcomes and is adjusted according to popula-
tion demographics and age-specific parameters (Fig. 1A).
The model was used to make a direct comparison of PCV-10
and PCV-13 given as three doses in the first 6 months of life, with
a booster at age 12 to 15 months as per latest recommendations.This model simulated in a birth cohort of 82,100 newborns the
disease process of IPD (meningitis and bacteremia), community-
acquired pneumonia (CAP), and AOM caused by S. pneumoniae and
NTHi within monthly cycles. Our analysis estimated the direct
impact of vaccination on children at risk (aged 09 years only)
by evaluating the cost-effectiveness and assuming that steady
state will be in place after 10 years, permitting the vaccination
program selected to have a consistent effect. This avoids includ-
ing additional assumptions on indirect effects and immunity in
the population over time.
Epidemiological Data
Demographic data for Hong Kong were obtained from the Census
and Statistics Department from the Government of the Hong
Kong Special Administrative Region for the year 2011 [15].
Data for incidence on IPD, CAP, and AOM were obtained from
published literature and local surveillance activities [4,16,17]. The
annual number of adult hospitalizations for IPD was obtained
Table 2 – Various assumptions for model para-
meters (PCV-10 vs. PCV-13).
Model parameters Combination of model
parameters
PCV-10 PCV-13
Indirect effect of IPD Not included [40] Included [36,39]
Efficacy of IPD 6A: 0%; 19A: 0%
[23]
6A: 94.7%; 3:
94.7%; 19A:
94.7% [23]
Efficacy of hospitalized
pneumonia
23.4% [28] 28.2%
Efficacy of pneumonia
(GP visit)
4.3% [25–28] 7.95%
Efficacy of NTHi AOM
(GP visit)
0%  0% [24]
Percent reduction in
myringotomy
23% [24] 29.6% [24]
Serotype 3
effectiveness
0%y 0% [34,35]
Vaccine price 195 HKD 420%
AOM, acute otitis media; GP, general practitioner; HKD, Hong Kong
dollars; IPD, invasive pneumococcal disease; NTHi, nontypeable
Haemophilus influenzae; PCV-10, pneumococcal nontypeable Haemo-
philus influenzae protein D conjugate vaccine; PCV-13, 13-valent
pneumococcal conjugate vaccine.
 Assumptions for different scenarios after discussions with local
experts.
y Serotype not included in this formulation.
VA L U E I N H E A LT H R E G I O N A L I S S U E S 2 ( 2 0 1 3 ) 6 4 – 7 468from the Hong Kong hospital authority as reported for the PCV-7
cost-effectiveness analysis, and for the number of pneumococcal
pneumonia cases in adults, all confirmed pneumococcal cases
were considered assuming that 32.0% of the unspecified cases
were due to S. pneumoniae [18]. Mortality data were obtained from
the Hong Kong Department of Health by considering data after
the introduction of PCV-7 [19].
Serotype distribution data for pneumococcal disease was
obtained from local hospital surveillance after the introduction of
PCV-7, in which the authors estimated the coverage for PCV-10 to
be 68.6% for those younger than 5 years, 66.7% for those aged 5 to
17 years, 53.3 for those aged 18 to 64 years, and 47.0% for those
65 years and older and for PCV-13, the coverage was reported
to be 91.4%, 73.3%, 78%, and 71.6% for the same age groups,
respectively. Serotype 3 represented 14.9% of the IPD cases in all
age groups [5].
Among AOM cases, we assumed that S. pneumoniae was the
etiologic agent in 35.9% of the AOM cases and 32.3% of the AOM
cases were attributable to NTHi [20]. The frequency of surgical
procedures (myringotomy) caused by AOM was based on data
from the recent publications of developed countries [21].
Cost Data
The cost of pneumococcal disease was determined from a payer
perspective corresponding to the public health service in Hong
Kong. Data were collected by following previously described
methodology [7] and updated to 2011, including hospitalization,
outpatient, and diagnostic tests for children and adults (Table 1).
For the base case, we assumed price parity for both vaccines, but
considering price differences in Hong Kong, these differences
were included in scenario analysis.
Quality of Life
Data from international published sources and previous cost-utility
analysis were used for our analysis, including disutilities associated
with IPD, CAP, and AOM and mean utilities for the general pop-
ulation by age groups [22,30–32]. Quality-of-life disutilities related
with acute episodes of the disease were adjusted to the average
period of acute episodes in days or weeks. In fact, disutilities
accounting for pain and hearing loss associated with chronic or
recurrent middle ear infection were not considered for AOM,
assuming a conservative scenario especially for NTHi-related cases.
Vaccine Effectiveness
Vaccine effectiveness (VE) was modeled to provide protection for
children from age 2 months to 10 years in a time-specific manner
with the ramp-up phase that occurs over the course of vaccine
administration (213 months), a full efficacy phase (13 months to
3 years), and a waning efficacy phase (310 years) (Fig. 1B).
Direct VE was estimated from clinical trials and postmarketing
studies in developed countries, such as the United States and
Canada, where PCV-7 has been studied longer [24,30]. The impact
of vaccination on IPD was calculated by using serotype-specific VE
and local serotype distribution of S. pneumoniae isolates in Hong
Kong. VE for serotypes 1, 5, and 7F contained in PCV-10 was
estimated as the average efficacy of PCV-7 serotypes reported by
Whitney et al. (94.7%) [23]. The same assumption was used for the
additional PCV-13 serotypes (1, 3, 5, 6A, 7F, and 19A). Although
serotypes 6A and 19A are not contained in PCV-10, they belong to
the same serogroups as 6B and 19F, respectively, which are included
in the vaccine. On the basis of the cross-reactivity of functional
antibodies elicited by PCV-10 and PCV-7 as well as postmarketing
effectiveness data of PCV-7, the partial protection of 76.0% against
6A was assumed for PCV-10 and no cross protection was assumed
for 19A in the base case but 26.0% was used in an alternativescenario [23,33]. Serotype 3 effectiveness data for PCV-13 have
not been documented yet, and early data on impact have not
confirmed any impact of this vaccine on this serotype [34,35]; then,
by considering the current epidemiological situation in which
serotype 3 is prevalent in Hong Kong, an alternative scenario has
been included in which effectiveness against this serotype is
excluded.
Recent data on pneumonia vaccine efficacy of PCV-10 have
suggested a similar impact on this disease for all conjugate
vaccines tested in different settings. All the clinical studies
evaluating the effect of vaccines on World Health Organization
(WHO) x-ray–defined pneumonia gave point efficacy estimates
against this end point of between 20.0% and 35.0%, with no
indication that vaccines with more serotypes provided corre-
spondingly greater protection against pneumonia [24–29]. In the
absence of PCV-13–specific estimates, the COMPAS efficacy esti-
mate of 23.4% against WHO x-ray–defined pneumonia was used
to determine reduction in pneumonia hospitalizations and the
efficacy against ambulatory pneumonia of the modeled vaccines
was assumed to be equal to that observed for PCV-7 in the
Northern California Kaiser Permanente Study (4.3%) on the
reduction of outpatient visits owing to pneumonia. For AOM,
vaccine efficacy was based on published evidence related to
randomized control trials [12,24,30].
We have considered the inclusion of indirect effects in our
analysis. Because there are no data available on the magnitude of
herd immunity and/or serotype replacement for PCV-10 and PCV-13,
we used a conservative assumption of equivalent indirect effects:
that is, we assumed herd protection of 15.4% for children younger
than 5 years and 29.0% for children older than 5 years as reported
by the Centers for Disease Control and Prevention for PCV-7 [36,37].
Vaccine efficacy parameters for all outcomes in this analysis are
listed in Table 1.
Table 3 – Base-case health and economic outcomes (PCV-10 vs. PCV-13).
Health outcomes PCV-10 PCV-13 Difference
Deaths 12 12 0
Cases of pneumococcal meningitis 5 3 2
Cases of pneumococcal bacteremia 19 15 4
Cases of CAP (hospitalized and outpatient) 70,174 70,174 0
Cases of AOM (myringotomies þ GP visits þ complications) 197,482 210,711 13,229
Economic outcomes PCV-10 (HKD) PCV-13 (HKD) Difference (HKD)
Vaccination cost 90,055,770 90,055,770 0
Pneumococcal meningitis cost 510,814 339,653 171,160
Pneumococcal bacteremia cost 1,309,547 1,010,127 299,420
Pneumonia cost (hospitalization þ outpatient) 1,004,690,133 1,004,694,282 4,149
AOM cost (GP þ myringotomies þ complications) 448,680,794 493,769,419 45,088,625
AOM, acute otitis media; CAP, community-acquired pneumonia; GP, general practitioner; HKD, Hong Kong dollars; PCV-10, pneumococcal
nontypeable Haemophilus influenzae protein D conjugate vaccine; PCV-13, 13-valent pneumococcal conjugate vaccine.
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We compared the outcomes obtained for both vaccines including
estimated number of deaths and cases for IPD, CAP (hospitalized
and nonhospitalized), and AOM including myringotomies and
ventilation tubes. We determined the difference in direct costs
(incremental cost) expressed in Hong Kong dollars (HKD) and the
effect reported as quality-adjusted life-years (QALYs) and life-
years (LYs) gained comparing PCV-10 and PCV-13 per year, which
is related to the defined health outcomes. The results are
provided undiscounted and discounted by using a 5.0% discount
rate. One-way sensitivity analysis was done by adjusting param-
eters on efficacy, epidemiology, and disease management (20%
and 95% confidence interval VE). One-way and two-way sensi-
tivity analyses were performed by using different combinations
of parameters after discussions with regional experts to include
some hypothetical considerations based on local interest pre-
sented in Table 2, populating the model in both sensitivity and
scenario analyses to examine their impacts on cost and effective-
ness outcomes. Last, we performed a probabilistic sensitivity
analyses to assess the robustness of the results and estimate the
range of model outcomes. For this we ran 1000 simulations by
using log-normal distribution for vaccine efficacy, beta distribu-Table 4 – Incremental cost-effectiveness in the base-cas
Total costs: QALYs, LYs, and ICERs PCV-10 PCV
Total costs (undiscounted) 1,545,247,058 1,589,8
Total costs (discounted) 641,860,544 675,99
Total LYs gained (undiscounted) 4,466,802 4,466
Total LYs gained (discounted) 1,497,975 1,497
Total QALYs gained (undiscounted) 3,706,410 3,706
Total QALYs gained (discounted) 1,242,615 1,242
ICER—undiscounted
Cost per LY gained (HKD)
Cost per QALY gained (HKD)
ICER—discounted
Cost per LY gained (HKD)
Cost per QALY gained (HKD)
HKD, Hong King dollars; ICER, incremental cost-effectiveness ratio; LY,
protein D conjugate vaccine; PCV-13, 13-valent pneumococcal conjug
Organization.
 PCV-13 is expected to generate more LYs with higher costs. Hong K
thresholds: highly cost-effective (less than GDP per capita), cost-effective
(more than three times GDP per capita) [38].
y PCV-10 is dominant because it exhibits both lower costs and higher nution for disease incidence rates and disutility values, and trian-
gular distribution for costs. In addition, a cost-effectiveness
acceptability curve was generated to summarize the potential
effect of uncertainty for Hong Kong.Results
Health Outcomes
Model projections indicated that PCV-13 and PCV-10 had approx-
imately equivalent impact on death prevention caused by IPD
and all-cause pneumonia (hospitalized and outpatient). PCV-10
was projected to prevent only two cases fewer of pneumococcal
meningitis and four cases of pneumococcal bacteremia fewer as
compared with PCV-13. PCV-10 was projected to prevent a greater
number of AOM cases (13,229 events) (Table 3).
Economic Outcomes
In terms of economic outcomes, by assuming a vaccine cost of
HKD 275 (including administration costs) for both PCV-10 and
PCV-13 (price parity), PCV-13 was expected to generate additionale analysis (PCV-10 vs. PCV-13).
-13 PCV-10 vs. PCV-13 incremental difference
69,275 44,622,217
4,429 34,133,885
,820 18
,981 6
,309 101
,525 90
2,440,360
– Dominanty
6,115,185
– Dominanty
life-year; PCV-10, pneumococcal nontypeable Haemophilus influenzae
ate vaccine; QALY, quality-adjusted life-year; WHO, World Health
ong GDP per capita is HKD 266,026 [40]. WHO cost-effectiveness
(between one and three times GDP per capita), and not cost-effective
mber of QALYs (effectiveness).
F
p
p
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tion was expected to save an additional HKD 44.62 million
(discounted by using a 5.0% discount rate) as compared with
PCV-13 vaccination. The overall savings of HKD 44.62 million were
largely linked to the reduction in AOM disease burden (myringot-
omy procedures and general practitioner visits) (Table 4).Cost-Effectiveness Outcomes
As shown in Table 3, vaccination with PCV-10 generated 90 (101
undiscounted) more QALYs with overall cost savings as compared
with PCV-13. The PCV-10 vaccination program was expected to be
cost saving as compared with the PCV-13 vaccination program.
However, PCV-13 is expected to generate an increase in
the number of LYs gained (18 LYs undiscounted and 6 LYs gained
discounted).One-Way Sensitivity Analysis
In Fig. 2, one-way sensitivity analysis showed that the results
were most sensitive to cost for inpatient myringotomy and the
changes in AOM-related parameters, but when these parameters
were changed, PCV-10 vaccination was still cost saving compared
with PCV-13 vaccination.ig. 2 – One-way sensitivity analysis. AOM, acute otitis media; GP,
neumococcal disease; NTHi, nontypeable Haemophilus influenzae
rotein D conjugate vaccine; PCV-13, 13-valent pneumococcal coScenario Analysis
The outcomes of one-way scenario analysis while varying one
assumption at a time are presented on the cost-effectiveness
plane in Fig. 3. This analysis showed that varying each assump-
tion had a moderate impact on the incremental cost except for
the percent reduction in myringotomy, which indicated a larger
impact on the incremental cost and led to a great reduction in
health benefit gained for PCV-10. The largest change in incre-
mental QALYs gained was due to the efficacy of NTHi AOM
(general practitioner visit). Most of the scenarios did not appear
to have an impact on the cost-effectiveness result, with PCV-10
vaccination remaining to be a cost-saving strategy.
Both incremental health and economic outcomes of the two-
way scenario analysis while varying two assumptions at a time
are presented on the cost-effectiveness plane in Fig. 4. For most
of the scenarios modeled, PCV-10 vaccination still generated
more QALYs gained with less cost, making the PCV-10 vaccina-
tion program dominant over the PCV-13 vaccination program.
Varying parameters for VE on AOM and its related procedures
had a significantly larger impact on the incremental cost, which
made PCV-10 an intervention to generate more QALYs gained but
incurred greater cost as compared with PCV-13. When we included
potential differences in the vaccine price (20.0% lower for PCV-10
as per the list price in Hong Kong), the cost offsets for PCV-10 were
much higher (HKD 47.3 million) than those for PCV-13.general practitioner; HKD, Hong Kong dollars; IPD, invasive
; PCV-10, pneumococcal nontypeable Haemophilus influenzae
njugate vaccine; QALY, quality-adjusted life-year.
Fig. 3 – One-way scenario analysis. AOM, acute otitis media; GP, general practitioner; HKD, Hong Kong dollars; IPD, invasive
pneumococcal disease; PCV-10, pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine; PCV-13, 13-
valent pneumococcal conjugate vaccine; QALY, quality-adjusted life-year; VE, vaccine effectiveness.
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The results from probabilistic sensitivity analysis indicated that in
93% of the simulations, PCV-10 dominates PCV-13 in terms of
QALYs gained and cost savings; 5% of the simulations indicate that
PCV-13 dominates PCV-10; last, only 2% and 1% of the simulations
estimate that PCV-10 generates more costs with higher QALYs
gained and less costs with lower QALYs, respectively (Fig. 5).Discussion
We developed an age-stratified Markov model to evaluate the
cost-effectiveness of PCV-10 compared with that of PCV-13 by
using parameters specific for Hong Kong. The strength of this
model for estimating the cost-effectiveness of PCV-10 was to
adjust VE against IPD by using epidemiological data specific for
Hong Kong. Universal infant vaccination with PCV-10 was pro-
jected to have the largest impact on AOM owing to the highest
disease frequency of AOM. Overall, in the base-case analysis,
universal infant PCV-10 vaccination was a cost-saving strategy
compared with PCV-13 vaccination from a payer perspective.
Marginal additional reductions in the number of cases of men-
ingitis and bacteremia were estimated for PCV-13. These differ-
ences are mainly due to an additional serotype coverage on IPD
cases included in PCV-13, especially serotype 3 in older age
groups and serotype 19A [5]. Hence, this additional protection
would lead to a subsequent limited increase in the number of LYs
gained associated with the low incidence of IPD and fatality ratio
associated, but with higher costs for the PCV-13 program.
In this study, a great effort has been made to do an extensive
review on both epidemiological and economic data from variouspublished sources, offering a comprehensive understanding of
how different model assumptions could impact clinical, eco-
nomic, and cost-effectiveness outcomes. We show in this study
that varying multiple model parameter assumptions at a time
can lead to changes in incremental cost, incremental effective-
ness, and cost-effectiveness results, thus influencing the vaccine
decision-making process.
Altogether, this model was tested in various scenario analyses
with different sets of combinations of model parameters. We
comprehensively tried out all the different scenarios of param-
eter combinations to examine how incremental cost and QALYs
gained were influenced in the two-way scenario analysis. In the
one-way scenario analysis, varying each of the eight assumptions
did not alter the cost-effectiveness results. Nevertheless, the
great marginal impact of the percent reduction in myringotomy
can be observed because a majority of the disease burden came
from AOM. More significant influence could be seen in the two-
way scenario analysis. The cost-effectiveness plane shown in
Fig. 4 demonstrates that varying assumptions of the indirect
effect and the percent reduction in myringotomy together had an
enormous impact on both incremental cost and QALYs gained.
Again, this is also sensible because the herd effect constitutes a
major proportion of health benefit compared with the direct
effect. In view of all the outcomes derived above, the validity and
rationality of the appropriate use of parameter assumptions
should then be carefully addressed before populating a vaccine
pharmacoeconomic model.
Because PCV-10 and PCV-13 have been available on the market
for only a few years, effectiveness data for both vaccines were
lacking and they have been approved only on the basis of
immunogenicity data. Therefore, a head-to-head comparison
Fig. 4 – Two-way scenario analysis. AOM, acute otitis media; GP, general practitioner; HKD, Hong Kong dollars; IPD, invasive
pneumococcal disease; PCV-10, pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine; PCV-13, 13-
valent pneumococcal conjugate vaccine; QALY, quality-adjusted life-year; VE, vaccine effectiveness.
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a PCV-7 randomized clinical trial to generate assumed effective-
ness against IPD, pneumonia, and AOM [41]. To date, it has been
very difficult, if not infeasible, to predict with any precision the
relative impact of one newer PCV formulation on another for
both pneumonia and AOM. Only recent data for the efficacy of
PCV-10 against pneumonia were available, and up to now,
previous economic evaluations have used different assumptions
to estimate specific VE. Few studies adopted the hypothesis that
pneumonia and AOM efficacy could be extrapolated and was
assumed to be proportional to the serotype distribution for IPD
[13,42,43]. Therefore, data from pneumonia efficacy trial (COM-
PAS) for PCV-10 were also applied to both PCV-10 and PCV-13,
which is supported by the evidence that more serotypes did not
necessarily provide greater protection against pneumonia [29,44].
Another vital factor is the estimation of the herd effect
because it usually brings forth many health benefits to the
unvaccinated population, which greatly improves the cost-
effectiveness results of a vaccination program [36,39]; the inclu-
sion of the herd effect of a vaccine in the base-case assumption is
now considered a standard practice and supported by the recent
reviews of the cost-effectiveness analysis of new vaccines [37,45].
Nevertheless, owing to the difficulty in acquiring a local estimate
of the herd effect in Hong Kong, we took a conservative approach.
The herd effect and the net indirect effect in children younger
than 5 years were assumed to be similar to what has been
observed in the United States after the introduction of PCV-7,
as estimated by the Centers for Disease Control and Prevention
National Immunization Survey [36,39].
Last, the implementation cost of the program could play a
significant role in the sustainability of the program because poten-
tial differences in this setting could influence the cost-effectiveness
outcomes. As mentioned by the WHO, PCV-10 and PCV-13 are safe
and effective. The selection of one of them depends on factors suchas local epidemiology, vaccine supply, and cost-effectiveness con-
siderations [46,47].
Limitations
There are some study limitations that need to be addressed. First,
the data regarding serotype replacement were not available; hence,
its effect was not modeled in this study. Second, the estimates of
the herd effect by IPD were difficult to evaluate and were extrapo-
lated by using data from the US experiences [36,39]. As a matter of
fact, it is currently very difficult to predict the degree of the herd
effect afforded by each vaccine in the adult population because of
the lack of information about the dynamic processes of serotype
replacement and interactions within a well-defined population
structure as a social contact structure varies from time to time
and from region to region [48]. Nevertheless, this limitation applies
to both interventions evaluated. Third, the societal perspective was
not evaluated because indirect cost data were not available and
limit the possibility to generalize our results. If the benefit of
reduction in indirect costs due to PCV-10 vaccination were to be
included, it would potentially make this program even more
favorable. Additional research considering the societal perspective
might be necessary in the future to ensure sustainability of the
selected vaccine program in Hong Kong. Finally, although method-
ologies such as Markov or decision tree modeling used to evaluate
the cost-effectiveness of pneumococcal vaccines are similar among
countries, the findings of Hong Kong cannot be generalized to other
countries owing to disparity in the epidemiology of pneumococcal
disease and economic profiles across different countries.
Conclusions
In conclusion, provided with the most updated epidemiological
and cost data available from various sources, the model projected
Fig. 5 – Probabilistic sensitivity analysis PCV-10 versus PCV-13 in Hong Kong. WHO highly cost-effectiveness threshold for
Hong Kong is less than GDP per capita (Hong Kong GDP per capita is HKD 266,026) [38,40]. GDP, gross domestic product; HKD,
Hong Kong dollars; PCV-10, pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine; PCV-13, 13-
valent pneumococcal conjugate vaccine; QALY, quality-adjusted life-year; WHO, World Health Organization.
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saving strategy compared with PCV-13 vaccination in the base-
case analysis, generating better cost offsets and higher QALY
gained. New evidence on real-life impact and implementation
costs of these vaccines along with local epidemiological data will
need to be considered by decision makers to determine the best
option to be used in coming years.Acknowledgments
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